Core One Labs Negotiates Milestone Acquisition With Akome Biotech Ltd. 
New to The Street – NEWSMAX Sunday April 17th 10AM EST Line Up Features Tonix Pharmaceuticals with CEO Seth Lederman, NativeCoin with President Randy Williams, Finxflo with CEO James Gillingham and More 
Holt Fitness Pivots to Online Coaching Amid the Pandemic Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020
CHICAGO, April 16, 2021 (GLOBE NEWSWIRE) — Cosmos Holdings, Inc. (“the Company”) (OTCQX: COSM), a…
Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
BOSTON, April 16, 2021 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company…
Vistin Pharma ASA: Invitation to Q1 2021 conference call
Oslo, Norway, 16 April 2021 Vistin Pharma ASA will release its first quarter 2021 results…
LIDDS Annual Report 2020
UPPSALA, SWEDEN – LIDDS publishes Annual Report for 2020 The Annual Report is attached to…
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
— Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00…
Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients, Caregivers, and Families at Virtual AAN 2021
Seizure Related Benefits noted by caregivers included reduction in frequency, fewer triggers causing seizures, and…
Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021
TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent…
Aleafia Health to Announce 2021 First Quarter Results
TORONTO, April 16, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia…
Immutep Receives A$1,155,055 R&D Tax Incentive
SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
Ublituximab demonstrated superiority versus teriflunomide in reducing annualized relapse rates and MRI brain lesions Ublituximab…